<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00024414</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068930</org_study_id>
    <secondary_id>THERADEX-P01-00-04</secondary_id>
    <secondary_id>JHOC-01011003</secondary_id>
    <secondary_id>PROTARGA-P01-00-04</secondary_id>
    <nct_id>NCT00024414</nct_id>
  </id_info>
  <brief_title>DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer</brief_title>
  <official_title>Phase II Open-Label Study of Taxoprexin (DHA-Paclitaxel) Injection by 2-Hour Intravenous Infusion in Patients With Metastatic Hormone-Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theradex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who&#xD;
      have metastatic prostate cancer that has not responded to hormone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective tumor response rate or prostate-specific antigen response,&#xD;
           duration of response, and time to disease progression in patients with metastatic&#xD;
           hormone-refractory prostate cancer treated with DHA-paclitaxel.&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this drug.&#xD;
&#xD;
        -  Determine the toxicity profile of this drug in these patients.&#xD;
&#xD;
        -  Assess the quality of life of patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive DHA-paclitaxel IV over 2 hours on day 1. Treatment repeats every 21 days in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, every 2 courses, and off study.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2001</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHA-paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Progressive metastatic disease on continuous hormonal therapy (e.g., orchiectomy&#xD;
                  or luteinizing hormone-releasing hormone (LHRH) agonist)&#xD;
&#xD;
               -  Progressive disease is defined by all of the following:&#xD;
&#xD;
                    -  Measurable disease or lesions on bone scan&#xD;
&#xD;
                    -  Increases in prostate-specific antigen (PSA) levels on at least 2&#xD;
                       consecutive measurements&#xD;
&#xD;
                    -  Continued PSA elevation after cessation of prior antiandrogen therapy (4&#xD;
                       weeks after flutamide and nilutamide and 8 weeks after bicalutamide)&#xD;
&#xD;
          -  PSA level at least 5 ng/mL&#xD;
&#xD;
          -  Serum testosterone level less than 50 ng/mL&#xD;
&#xD;
               -  Patients who have not undergone prior surgical castration should continue primary&#xD;
                  androgen suppression (LHRH agonist)&#xD;
&#xD;
          -  No known or clinical evidence of CNS metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT or SGPT no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled ventricular arrhythmia&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No superior vena cava syndrome&#xD;
&#xD;
        Neurologic:&#xD;
&#xD;
          -  No peripheral neuropathy greater than grade 1&#xD;
&#xD;
          -  No uncontrolled major seizure disorder&#xD;
&#xD;
          -  No spinal cord compression&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No psychiatric disorder that would preclude informed consent&#xD;
&#xD;
          -  No unstable or serious concurrent medical condition&#xD;
&#xD;
          -  No concurrent serious infection requiring parenteral therapy&#xD;
&#xD;
          -  No other prior or concurrent malignancy except:&#xD;
&#xD;
               -  Curatively treated nonmelanoma skin cancer OR&#xD;
&#xD;
               -  Other cancer curatively treated with surgery alone that has not recurred for more&#xD;
                  than 5 years&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 6 months&#xD;
             after study therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior taxanes&#xD;
&#xD;
          -  Prior mitoxantrone or prednisone for metastatic disease allowed&#xD;
&#xD;
          -  At least 28 days since prior chemotherapy and recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior samarium SM 153 lexidronam pentasodium or strontium chloride Sr 89&#xD;
&#xD;
          -  Prior external radiotherapy for metastatic disease allowed&#xD;
&#xD;
          -  At least 28 days since prior large-field radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy, including whole-brain radiotherapy for documented CNS&#xD;
             metastasis&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 14 days since prior major surgery and recovered&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior nonhormonal treatment for metastatic disease&#xD;
&#xD;
          -  At least 28 days since prior herbal preparations (e.g., PC-SPES) and recovered&#xD;
&#xD;
          -  No other concurrent anticancer medications&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A. Carducci, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Oncology Associates</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712-2254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta Bates Comprehensive Cancer Center</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucille Parker Markey Cancer Center, University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center - Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130-3932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - East Orange</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kimmel Cancer Center of Thomas Jefferson University - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-5541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2003</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 23, 2008</last_update_submitted>
  <last_update_submitted_qc>July 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2008</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

